Research ArticleAlzheimer’s Disease

Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease

See allHide authors and affiliations

Science Translational Medicine  05 Mar 2014:
Vol. 6, Issue 226, pp. 226ra30
DOI: 10.1126/scitranslmed.3007901

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

  • Increased brain tau sequestration and its longitudinal reduction in CSF in advanced AD
    • Nunzio Pomara, Director, Geriatric Psychiatry Division
    • Other Contributors:

    Fagan and colleagues (1) recently reported a surprising finding from a longitudinal study in carriers and non carriers of autosomal-dominant Alzheimer's disease (ADAD) mutations. They showed that in mutation carriers, the concentrations of a number of CSF markers of neuronal death/injury including tau, ptau181 (phosphorylated tau) and VILIP-1 (visin-like protein-1), increased in those in the asymptomatic phase, 10 to...

    Show More
    Competing Interests: None declared.

Stay Connected to Science Translational Medicine